Sarepta Therapeutics (SRPT) Competitors $19.03 +1.71 (+9.87%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$19.02 -0.02 (-0.08%) As of 07/8/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRPT vs. CTMX, EDIT, LEGN, GRFS, TGTX, LNTH, NUVL, TLX, AXSM, and ADMAShould you be buying Sarepta Therapeutics stock or one of its competitors? The main competitors of Sarepta Therapeutics include CytomX Therapeutics (CTMX), Editas Medicine (EDIT), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), Lantheus (LNTH), Nuvalent (NUVL), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Sarepta Therapeutics vs. Its Competitors CytomX Therapeutics Editas Medicine Legend Biotech Grifols TG Therapeutics Lantheus Nuvalent Telix Pharmaceuticals Axsome Therapeutics ADMA Biologics CytomX Therapeutics (NASDAQ:CTMX) and Sarepta Therapeutics (NASDAQ:SRPT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk. Which has more volatility & risk, CTMX or SRPT? CytomX Therapeutics has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Do insiders & institutionals have more ownership in CTMX or SRPT? 67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 6.6% of CytomX Therapeutics shares are held by insiders. Comparatively, 7.7% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts prefer CTMX or SRPT? CytomX Therapeutics presently has a consensus target price of $5.33, indicating a potential upside of 122.22%. Sarepta Therapeutics has a consensus target price of $60.88, indicating a potential upside of 219.89%. Given Sarepta Therapeutics' higher probable upside, analysts plainly believe Sarepta Therapeutics is more favorable than CytomX Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytomX Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Sarepta Therapeutics 1 Sell rating(s) 12 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.44 Does the media refer more to CTMX or SRPT? In the previous week, Sarepta Therapeutics had 40 more articles in the media than CytomX Therapeutics. MarketBeat recorded 42 mentions for Sarepta Therapeutics and 2 mentions for CytomX Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.16 beat CytomX Therapeutics' score of 0.00 indicating that Sarepta Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sarepta Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 30 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Is CTMX or SRPT more profitable? CytomX Therapeutics has a net margin of 28.22% compared to Sarepta Therapeutics' net margin of -11.12%. Sarepta Therapeutics' return on equity of -14.88% beat CytomX Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CytomX Therapeutics28.22% -553.71% 32.21% Sarepta Therapeutics -11.12%-14.88%-5.12% Which has stronger valuation & earnings, CTMX or SRPT? Sarepta Therapeutics has higher revenue and earnings than CytomX Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytomX Therapeutics$138.10M1.40$31.87M$0.485.00Sarepta Therapeutics$1.90B0.98$235.24M-$2.69-7.07 SummarySarepta Therapeutics beats CytomX Therapeutics on 9 of the 16 factors compared between the two stocks. Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRPT vs. The Competition Export to ExcelMetricSarepta TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.70B$2.88B$5.47B$8.95BDividend YieldN/A2.46%5.25%4.06%P/E Ratio-7.0720.8027.0020.10Price / Sales0.98286.98435.75120.29Price / Cash7.1141.1936.8257.86Price / Book1.197.487.985.56Net Income$235.24M-$55.04M$3.16B$248.40M7 Day Performance4.62%2.44%2.40%4.67%1 Month Performance-52.08%1.90%2.19%6.64%1 Year Performance-87.33%4.35%33.82%21.31% Sarepta Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRPTSarepta Therapeutics4.7089 of 5 stars$19.03+9.9%$60.88+219.9%-87.4%$1.70B$1.90B-7.071,372Trending NewsHigh Trading VolumeCTMXCytomX Therapeutics3.9181 of 5 stars$2.27+0.9%$5.33+134.9%+84.6%$183.01M$147.56M4.73170EDITEditas Medicine4.1811 of 5 stars$2.20-3.5%$4.70+113.6%-40.7%$184.17M$35.84M-0.72230LEGNLegend Biotech3.0504 of 5 stars$35.49+2.5%$76.20+114.7%-20.9%$6.52B$627.24M-60.152,609Positive NewsAnalyst ForecastGRFSGrifols4.0825 of 5 stars$9.04+2.0%$10.30+13.9%+7.0%$6.22B$7.81B7.7323,822News CoverageAnalyst UpgradeTGTXTG Therapeutics3.89 of 5 stars$35.99-2.0%$40.80+13.4%+82.1%$5.71B$386.39M149.96290News CoveragePositive NewsLNTHLantheus4.4152 of 5 stars$81.86+0.5%$130.50+59.4%+4.6%$5.66B$1.53B23.26700NUVLNuvalent3.7406 of 5 stars$76.30-4.2%$119.60+56.7%+8.9%$5.48BN/A-17.3840TLXTelix PharmaceuticalsN/A$16.07+0.4%$22.00+36.9%N/A$5.44B$516.72M0.00N/AAXSMAxsome Therapeutics4.7718 of 5 stars$104.39+1.0%$172.33+65.1%+29.6%$5.09B$432.16M-18.09380ADMAADMA Biologics4.1295 of 5 stars$18.21+0.3%$27.67+51.9%+53.0%$4.35B$426.45M21.42530Positive News Related Companies and Tools Related Companies CytomX Therapeutics Competitors Editas Medicine Competitors Legend Biotech Competitors Grifols Competitors TG Therapeutics Competitors Lantheus Competitors Nuvalent Competitors Telix Pharmaceuticals Competitors Axsome Therapeutics Competitors ADMA Biologics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRPT) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
